Core Viewpoint - Nanxin Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of annual report information disclosure, leading to the termination of its cash acquisition of Future Pharmaceutical assets due to failure to reach consensus on key terms [1] Financial Adjustments - The company corrected prior accounting errors, resulting in a reduction of 2023 revenue by 24.5397 million yuan, which is 3.4% of the total annual revenue [1] - The correction significantly impacted the company's net profit, changing from a profit of 3.7515 million yuan to a loss of 10.8687 million yuan for 2023, fundamentally altering the profit-loss status [1] - Due to the retrospective adjustment of accounting errors, the company also revised its financial data for multiple reports in 2024, with the Q1-Q3 2024 revenue adjusted from 226.5709 million yuan to 251.1106 million yuan, an increase of 24.5397 million yuan; the net profit for the same period was adjusted from a loss of 71.8361 million yuan to a loss of 57.2159 million yuan [1]

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, which may lead to civil compensation claims from affected investors [1]. Group 1: Investigation and Legal Actions - The CSRC has decided to initiate an investigation against Nanxin Pharmaceutical due to alleged violations of information disclosure laws as per the Securities Law and Administrative Penalty Law of the People's Republic of China [1]. - Investors who have suffered losses due to the company's alleged fraudulent activities can file civil compensation claims, which may include investment differences, commissions, and stamp duties [1]. - A lawyer from Shanghai Hanlian Law Firm is actively seeking to represent affected investors in compensation lawsuits against Nanxin Pharmaceutical [1]. Group 2: Compensation Conditions - The conditions for compensation claims include investors who purchased Nanxin Pharmaceutical's stocks or bonds before October 1, 2025, and either sold or continued to hold them after this date [1]. - The final conditions for compensation will be adjusted based on the conclusions of the CSRC's administrative penalties and the court's final judgment regarding the legal timeline, compensation targets, and standards [2]. - Investors are advised that while they can initiate lawsuits without the administrative penalty decision, doing so may carry risks of losing the case due to limited investigative means [2]. Group 3: Documentation for Claims - Investors wishing to register for compensation must provide specific documentation, including a copy of their ID, original securities account opening confirmation, and original transaction records from the first purchase to the present [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 上海久诚律师事务所许峰律师团提示，南新制药（维权）（688189）涉嫌虚假陈述引发的投资者索赔案 已经启动。（许峰律师专栏） 2025年10月1日，南新制药（688189）公告近日收到证监会出具的《立案告知书》，因公司涉嫌年报信 息披露违法违规，根据《证券法》《行政处罚法》等法律法规，证监会决定对公司立案。 许峰律师认为，暂定在2025年10月1日之前买入南新制药股票，并且在2025年10月1日后卖出或继续持有 股票的投资者，已可发起索赔。（南新制药维权入口） 除了南新制药投资者索赔案启动，许峰律师代理的腾茂科技（873789）股票操纵索赔案已获得法院立 案，目前正在等待法院的下一步安排，律师团队同步还在继续推进后续案件的立案工作，还在继续接受 其他投资者的索赔委托。 2024年10月28日，证监会对刘洪涛等操纵腾茂科技（873789）股票案作出行政处罚。经查明,刘洪涛、 娄阁存在以下违法事实: 一、刘洪涛、娄阁共同操纵的合作模式 二、刘洪涛、娄阁控制使用证券账户的情况 2023年6月19日至9月28日(以下简称操纵期间),刘洪涛、娄阁实际控制"娄阁"东方财富 ...

消息面上，南新制药发布公告称，公司近日收到中国证监会出具的《立案告知书》。因公司涉嫌年报信 息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会决定对公司立案。 北京商报讯（记者 丁宁）10月9日，南新制药（688189）以跌停开盘，报跌停价9.1元/股，跌幅为 19.96%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688189 证券简称：南新制药 公告编号：2025-043 湖南南新制药股份有限公司 关于收到中国证券监督管理委员会《立案告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 湖南南新制药股份有限公司（以下简称"公司"）近日收到中国证券监督管理委员会(以下简称"中国证监 会")出具的《立案告知书》（编号：证监立案字0132025024号）。因公司涉嫌年报信息披露违法违规， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立 案。 立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照相关法律法规及监管要求及时履行 信息披露义务。 公司指定信息披露媒体为上海证券交易所网站（www.sse.com.cn）和《上海证券报》《中国证券报》 《证券日报》《证券时报》，公司相关信息均以在上述指定媒体刊登的公告为准。敬请广大投资者理性 投资，注意投资风险。 特此公告。 湖南南新制药股份有限公司董事会 2025年10月1日 ...

Key Points - Hainan Huatie's shareholder Hu Danfeng has terminated the share reduction plan and plans to increase holdings in the company with an investment of no less than 30 million yuan and no more than 50 million yuan [2] - Yonghe Co. expects a net profit increase of 447.64% to 506.85% year-on-year for Q3 2025, driven by the high demand in the refrigerant industry and product optimization [3] - Delis Co. is planning a change in company control, leading to a suspension of its stock from October 9, 2025 [4] - BYD reported September 2025 sales of 396,300 new energy vehicles, a slight decrease from 419,400 units in the same month last year, while cumulative sales for the year reached 3.26 million units, up 18.64% [5] - Chipone Technology expects Q3 2025 revenue of 1.284 billion yuan, marking a historical high for the company, with a year-on-year increase of 78.77% [7] - Chipone anticipates a significant improvement in profitability for Q3 2025, with new orders expected to reach 1.593 billion yuan, a year-on-year increase of 145.80% [8] - ST Zhengping's stock will be suspended from trading starting October 9, 2025, due to unusual stock price fluctuations [2][28] - Huanxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [14] - Sichuan Gold won exploration rights for a gold mine in Xinjiang for 510 million yuan, indicating strong geological potential [15]

Group 1 - Nanjing Pharmaceutical (688189.SH) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation due to suspected violations in annual report disclosures [1] - The company will actively cooperate with the CSRC during the investigation and will fulfill its information disclosure obligations in accordance with relevant laws and regulations [1] Group 2 - Nanjing Pharmaceutical has announced the termination of its major asset restructuring plan, which involved a cash acquisition of assets from Future Pharmaceutical [2][3] - The proposed acquisition was valued at no more than 480 million yuan and included both listed and in-development products related to trace element injection solutions [2] - The company had previously signed a letter of intent for the acquisition but failed to reach an agreement on core terms after multiple discussions [3] Group 3 - Nanjing Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and raised a total of 1.223 billion yuan [3] - The company’s initial public offering (IPO) raised a net amount of 1.135 billion yuan, exceeding the originally planned amount by 466 million yuan [3] - The total issuance costs for the IPO amounted to 87.6177 million yuan, with the lead underwriter, Western Securities, receiving 71.1075 million yuan [3] Group 4 - In 2022, Nanjing Pharmaceutical implemented a capital reserve distribution plan, increasing its total share capital from 140 million shares to 196 million shares by distributing 0.4 shares for every share held [4] - In 2023, the company executed another capital reserve distribution, raising its total share capital to 274.4 million shares with a similar distribution of 0.4 shares for every share held [4]

Group 1 - Nanjing Pharmaceutical (688189) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation into alleged violations of annual report information disclosure [1] - During the investigation, the company will actively cooperate with the CSRC and fulfill its information disclosure obligations in accordance with relevant laws and regulations [1] Group 2 - Nanjing Pharmaceutical announced the termination of a major asset restructuring plan, which was initially disclosed on August 27, 2025, involving a cash acquisition of assets from Future Pharmaceutical [4][6] - The proposed transaction was valued at no more than 480 million yuan, including both listed and in-development products related to microelement injection solutions [6] - Despite multiple discussions and negotiations regarding the feasibility and core terms of the transaction, the parties could not reach an agreement, leading to the decision to terminate the deal [6] Group 3 - In the first half of the year, Nanjing Pharmaceutical reported a revenue of 61.846 million yuan, a decrease of 71.28% compared to the same period last year [8] - The company incurred a net loss attributable to shareholders of 40.002 million yuan, with a net loss of 41.731 million yuan after excluding non-recurring gains and losses [8][9] - As of September 30, the company's stock price was 11.37 yuan per share, reflecting a slight decline of 0.61% [8]

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. announced the termination of a major asset restructuring plan and is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report disclosure laws, indicating a challenging situation for the company in a competitive and regulated pharmaceutical industry [1][2]. Group 1: Investigation and Financial Performance - The CSRC has initiated an investigation into Nanxin Pharmaceutical due to suspected violations related to annual report disclosures, which could significantly impact investor perceptions of the company's value [2]. - The company's financial performance has shown a decline, with reported revenues of 720 million yuan in 2023, a net loss of 11 million yuan, and further losses in subsequent years, including a revenue of 263 million yuan and a net loss of 357 million yuan in 2024 [2]. - The ongoing investigation requires the company to issue monthly risk warning announcements and quarterly updates on the investigation's progress, with potential severe consequences if found guilty of major violations [2]. Group 2: Termination of Restructuring - Nanxin Pharmaceutical announced the termination of its major asset restructuring plan, which began on August 27, 2025, due to a lack of consensus on key terms among the parties involved [3]. - The company emphasized that the decision to terminate the restructuring was made to protect the interests of the company and its shareholders, and it will not adversely affect its existing business or financial status [3][4]. - The company is committed to not planning any major asset restructuring for one month following the announcement and will continue to seek investment and cooperation opportunities to enhance its product matrix and company value [4]. Group 3: Shareholder Actions - Major shareholder Guangzhou Qianyuan Investment Consulting Partnership plans to reduce its stake by up to 3% (approximately 8.232 million shares) starting October 27, 2025, due to funding needs [5]. - The shareholder currently holds 43.12 million shares, representing a 15.71% stake, and previously made a commitment not to transfer shares within 12 months of the company's IPO [5][6]. - The combination of the investigation, termination of restructuring, and shareholder reduction may negatively impact market expectations and investor confidence in the company [6].

Core Points - Nanjing Pharmaceutical (688189) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, leading to a formal investigation [2] - The planned major asset restructuring has been terminated, which was initially aimed at acquiring assets from Future Medicine for up to 480 million yuan [3] - The company reported a revenue of 61.8463 million yuan and a net loss of 40.0023 million yuan in the first half of the year [2] Group 1 - The CSRC issued a notice of investigation to Nanjing Pharmaceutical due to alleged violations in annual report disclosures [2] - The company will cooperate with the CSRC during the investigation and will fulfill its information disclosure obligations as required by law [2] - The planned acquisition of Future Medicine was announced on August 27, 2025, but the parties could not reach an agreement on core terms, leading to the termination of the restructuring plan [3] Group 2 - Nanjing Pharmaceutical emphasized that the termination of the asset restructuring will not adversely affect its business operations or financial status [3] - The company plans to continue pursuing its strategic goals and seek development opportunities through investments, mergers, and collaborations to enhance its product offerings and profitability [4]